Literature DB >> 11124835

RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing--cysteine-rich protein with Kazal motifs.

K Furumoto1, S Arii, A Mori, H Furuyama, M J Gorrin Rivas, T Nakao, N Isobe, T Murata, C Takahashi, M Noda, M Imamura.   

Abstract

The RECK (reversion-inducing-cysteine-rich protein with Kazal motifs) gene was initially isolated as a transformation suppressor gene. It encodes a membrane-anchored glycoprotein with multiple serine protease inhibitor-like domains. The RECK gene is expressed widely in normal organs but is undetectable in many tumor-derived cell lines. When artificially expressed in such cell lines, RECK suppresses their invasive and metastatic activities. Clinical implications of these findings, however, remained undefined because of the lack of studies using fresh human tumor samples. In the present study, we have addressed this issue by analyzing the levels of RECK gene expression in hepatocellular carcinoma (HCC). RECK mRNA was detectable by RNA blot hybridization in all the tumorous and contiguous nontumorous tissues obtained from 64 patients with HCC. In 26 cases, the RECK expression in tumorous tissues was higher than that in nontumorous tissues. The expression of RECK protein in these tissues could also be demonstrated by immunohistochemistry. Patients with high RECK mRNA expression in tumorous tissues tended to show better survival (P =.02), and such tumors had a tendency to be less invasive. Univariate and multivariate analysis revealed that the RECK mRNA expression is a novel and independent variable affecting overall survival (P =.01). These findings support the hypothesis that RECK has negative effects on the invasiveness of HCC cells and suggest the feasibility of RECK mRNA as a promising prognostic molecular marker for HCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11124835     DOI: 10.1053/jhep.2001.21048

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

1.  Low expression of RECK indicates a shorter survival for patients with invasive breast cancer.

Authors:  Yue Zhang; Shaoqiang Cheng; Guoqiang Zhang; Wenjie Ma; Yang Liu; Rui Zhao; Qingyuan Zhang; Da Pang
Journal:  Cancer Sci       Date:  2012-04-19       Impact factor: 6.716

2.  Estrogen suppresses expression of the matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs (RECK) within the mouse uterus.

Authors:  Xuan Zhang; Caitlin Healy; Warren B Nothnick
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

3.  Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases.

Authors:  N Namwat; J Puetkasichonpasutha; W Loilome; P Yongvanit; A Techasen; A Puapairoj; B Sripa; W Tassaneeyakul; N Khuntikeo; S Wongkham
Journal:  J Gastroenterol       Date:  2010-11-13       Impact factor: 7.527

4.  High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity.

Authors:  Man Chen; Yao Liu; Patrick Varley; Ying Chang; Xing-Xing He; Hai Huang; Daolin Tang; Michael T Lotze; Jusheng Lin; Allan Tsung
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

5.  TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118.

Authors:  J Oh; T Diaz; B Wei; H Chang; M Noda; W G Stetler-Stevenson
Journal:  Oncogene       Date:  2006-02-20       Impact factor: 9.867

6.  Association between polymorphisms in tumor suppressor genes and oncogenes and risk of hepatocellular carcinoma: a case-control study in an HCC epidemic area within the Han Chinese population.

Authors:  Chenghao Su; Yong Lin; Jianjun Niu; Lin Cai
Journal:  Med Oncol       Date:  2014-11-21       Impact factor: 3.064

7.  Differential expression of degradome components in cutaneous squamous cell carcinomas.

Authors:  Nijaguna B Prasad; Anne C Fischer; Alice Y Chuang; Jerry M Wright; Ting Yang; Hua-Ling Tsai; William H Westra; Nanette J Liegeois; Allan D Hess; Anthony P Tufaro
Journal:  Mod Pathol       Date:  2013-12-20       Impact factor: 7.842

Review 8.  The prognostic molecular markers in hepatocellular carcinoma.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

Review 9.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

10.  Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma.

Authors:  Umberto Cillo; Alessandro Vitale; Marco Bassanello; Patrizia Boccagni; Alberto Brolese; Giacomo Zanus; Patrizia Burra; Stefano Fagiuoli; Fabio Farinati; Massimo Rugge; Davide Francesco D'Amico
Journal:  Ann Surg       Date:  2004-02       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.